Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07397325 | Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia | PHASE1 | NOT YET_RECRUITING | 60 | — | — | Apr 16, 2026 | Dec 7, 2026 | Apr 13, 2026 | 2 | Brazil, Italy |
Amount of hair loss during chemotherapy treatment measured by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0. The Common Terminology Criteria for Adverse Events is a common terminology developed by the National Cancer Institute to describe and grade adverse events related to cancer therapy.
| Arm | Type | Description |
|---|---|---|
| DA-020 | ACTIVE_COMPARATOR | Topical DA-020 Solution |
| Placebo | PLACEBO_COMPARATOR | Topical Placebo Solution |
| DA-020 and Hyperforin (1.5%) | ACTIVE_COMPARATOR | DA-020 and Hyperforin (1.5%) |
| Name | Type | Description |
|---|---|---|
| DA-020 | DRUG | 7mL application of DA-020 (Topical Oxymetazoline) |
| Placebo | DRUG | Topical placebo solution |
| DA-020 and Hyperforin | DRUG | 7mL application of DA-020 (Topical Oxymetazoline) and Hyperforin (1.5%) |
Inclusion Criteria: * Diagnosed with stage I or stage II breast cancer * Scheduled but not begun, at least 4 cycles of taxane and/or anthracycline-based chemotherapy. * Ages 18-65 * Able to give informed consent Exclusion Criteria: * Resting blood pressure outside the range of 105-140/ 55-99 * Un...